104 results about "Beta-D-Glucopyranose" patented technology

The invention relates to wild honeysuckle flower extract, which mainly comprises the following compositions: macranthoside A,II b, macranthoside B,IIIb, 3-O-alpha-L-pyran rhamnose (1-2)-alpha-L-pyran arabinose-hederagenin and 3-O-beta-D-glucopyranose (1-4)-beta-D-glucopyranose (1-3)-alpha-L-pyran rhamnose (1-2)-alpha-L-pyran arabinose -oleanolic acid. The invention also relates to a method for preparing the compound and application of the compound in the aspect of cancer.

The invention discloses an abelmoschus manihot polysaccharide with an anti-tumor activity and a preparation method thereof. The polysaccharide is formed by beta-D-glucopyranose, alpha-D-mannopyranose, alpha-D-galactose and alpha-L-fucopyranose in a mol ratio of 1: 0.91: 2.14: 1.0, and has the molecular weight of 8867. The structural formula of a basic unit of the polysaccharide is that alpha-D-galactose (1->6) and alpha-D-mannopyranose (2->6) are taken as main chains and mannose C-3 branches are connected with the alpha-L-fucopyranose (1->3) and connected with the beta-D-glucopyranose (->1). According to the abelmoschus manihot polysaccharide disclosed by the invention, an extraction and separation process is selected through a large number of experiments; firstly, a water extraction and alcohol precipitation method is used for obtaining a rough polysaccharide and then protein is removed; and then, a DEAE-52 (Diethyl Aminoethanol-52) cellulose resin and SephadexG-100 gel resin are combined for purifying to prepare the abelmoschus manihot polysaccharide with high purity. Anti-tumor experiment results show that the abelmoschus manihot polysaccharide has very good anti-tumor activity and has no untoward effects after being used for a long period; and the abelmoschus manihot polysaccharide can be conveniently prepared into medicines with various preparations with pharmaceutically acceptable carriers, and is convenient to take clinically.

The invention discloses a bulk drug for treating orthopaedic diseases. The bulk drug is Chinese teasel root saponin VI and is prepared by extracting traditional Chinese medicinal materials which contain the Chinese teasel root saponin VI; the weight percentage content of the Chinese teasel root saponin VI occupies 95.0 to 99.9 percent of the total amount of an extract of the Chinese teasel root saponin VI; and the chemical name of the bulk drug is 3-O-alpha-L-arabopyranose ivy sapogenin-28-O-beta-D-glucopyranose(1-6)-beta-D-glucopyranoside. The invention also discloses a method for preparing the bulk drug - the Chinese teasel root saponin VI. The method comprises the following steps of extraction, concentration, separation of the total saponin, decolorization and purification and refinement. The preparation method has the advantages that the preparation method has high extraction rate and low cost, is safe and environment-friendly and is suitable for industrialized mass production. The invention also provides application of the bulk drug in preparing medicines for preventing and treating the orthopaedic diseases including osteoporosis, fracture and osteoarthritis.

The invention relates to 24(R)-pseudoginsenoside-GQ as well as a semisynthesis method and medicinal application thereof, belonging to a new compound as well as a synthesis method and medicinal application thereof. In the invention, 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 is used as a raw material, and under an acid condition, a new compound is synthesized through the steps of oxidization, cyclization, and the like, wherein the chemical name of the new compound is 3-O-[beta-D-glucopyranose-(1-2)-beta-D-glucopyranose group]-damma-20S, 24R-epoxy-3beta, 12beta, 25-triol being short for 24(R)-pseudoginsenoside-GQ, the productivity of which reaches higher than 80 percent. The 24(R)-pseudoginsenoside-GQ has wide medicinal application in preparing medicaments for treating coronary heart diseases, myocardial ischemia, ischemic shocks, arrhythmia and reperfusion damages and resisting cancer.

The invention discloses gynostemma pentaphylla secondary saponin, a preparation method of the gynostemma pentaphylla secondary saponin and applications of the gynostemma pentaphylla secondary saponin, and relates to gynostemma pentaphylla. The name of a compound of the gynostemma pentaphylla secondary saponin is 2Alpha, 3Beta, 12Beta, 20(S)-tetrahydroxy-24-dammarene-3-O-Beta-D-glucopyranose-(1--2)-Beta-D- glucopyranoside. Gynostemma pentaphylla saponin is prepared and is converted by microbe, and the gynostemma pentaphylla secondary saponin is prepared. By the antitumor activity determination of the compound, the gynostemma pentaphylla secondary saponin is proved to be used for preparing an antitumor activity agent. The gynostemma pentaphylla secondary saponin is prepared by a microbial conversion method, and the gynostemma pentaphylla is taken as raw materials, is planted in a large area in China, is low in cost and easy to obtain, and rich in resources, so that the gynostemma pentaphylla secondary saponin is a good material for developing and applying biological medicines and health care products; the process steps are simple, macroporous adsorption resin is adopted as a main preparation filler, and the gynostemma pentaphylla secondary saponin is suitable for scale amplification; and compared with a chemical acid-base cracking method, the preparation method has the advantages that the requirements for equipment conditions are simple, and the side effects of the prepared product is little.

The invention provides the application method of 1,3-di-O-Galloyl-acyl 1-4,6-(S)-HHDP-Beta-D-glucoseglucopyranose in preparing tumor antitumor drugs, in particular the application of glucoseglucopyranose in preparing inducing agent to inhibit the growth of tumor cells and to accelerate tumor cell apoptosis. The invention also provides a tumor antitumor drug, which contains 5 to 20 percent of 1,3-di-O-Galloyl-acyl 1-4,6-(S)-HHDP-Beta-D-glucoseglucopyranose.

The invention relates to a compound with effects of resisting inflammation and platelet activation and aggregation as well as a preparation method and application thereof. The compound has the structure of (25R)-26-oxy-beta-D-glucopyranose-5alpha-furostanol-3beta,12beta,22,26-tetraalcohol-3-oxy-beta-D-glucopyranose(1->2)[beta-D-glucopyranose(1->3)]-beta-D-glucopyranose(1->4)-beta-D-galapyranoside. The effects of the compound in the field of cardial vessels are comprehensively researched from platelet aggregation, platelet activation, platelet calcium ion variation, platelet activation signal transduction pathway and expression of platelet activation relevant inflammatory factors in the invention for the first time. Results show that the compound is a substance found to be with a strong effect on resisting platelet aggregation so far in the allium macrostemon saponin compounds, which has the stronger effect than that of aspirin with the same concentration; and the compound simultaneously has an obvious effect on resisting relevant platelet inflammations. The compound provided by the invention can be applied to medicines for treating thrombus and atherosclerosis.

The invention belongs to the technical field of medicines and provides a 3-O-alpha-L-pyran rhamnose-(1->2) [beta-D-glucopyranose-(1-4)]-alpha-L-pyran arabinose hederasaponin derivative, a preparation method of salts thereof and application thereof to resisting tumor. The structures of the hederasaponin 3-O-alpha-L-pyran rhamnose-(1->2) [beta-D-glucopyranose-(1->4)]-alpha-L-pyran arabinose hederasaponin derivative and salts thereof are shown as follows. The hederasaponin 3-O-alpha-L-pyran rhamnose-(1->2) [beta-D-glucopyranose-(1->4)]-alpha-L-pyran arabinose hederasaponin derivative and the salts thereof are combined with a pharmaceutical acceptable carrier to form a pharmaceutical compound which is used for preparing tumor-resistant medicines. Compared with the prototype medicine, a medicine containing the ingredient derivative and the salts thereof has considerable or stronger tumor-resistant activity; and meanwhile, the activity of other tumor-resistant medicines can be obviously enhanced and the side effects of the medicines are reduced.

The invention relates to 2-deoxy-2-isorhodanate-1,3,4,6-tetra-O-benzyl-beta-D-glucopyranose. The invention also relates to a synthetic method for 2-deoxy-2-isorhodanate-1,3,4,6-tetra-O-benzyl-beta-D-glucopyranose. The synthetic method comprises the following concrete steps: reacting 2-deoxy-2-amino-1,3,4,6-tetra-O-benzyl-beta-D-pyranose hydrochloride and carbon disulfide with triethylamine; and then reacting a reaction product with p-toluene sulfonyl chloride so as to obtain 2-deoxy-2-isorhodanate-1,3,4,6-tetra-O-benzyl-beta-D-glucopyranose, wherein acetonitrile is used as a solvent for the reaction, reaction temperature is 0 DEG C, and reaction time is 1 to 2 h. The synthetic method has the advantages of easy and safe operation, small environmental pollution, high yield and simple post-treatment. The prepared 2-deoxy-2-isorhodanate-1,3,4,6-tetra-O-benzyl-beta-D-glucopyranose can be used as an organic synthesis intermediate for synthesis of a glucosamine derivative.

The invention discloses a method for testing quality of reineckea carnea medicinal materials, which includes part or whole of description, identification, examination and content measurement. The aforementioned is indicated as a thin-layer chromatography identification of kitigenin and/or kitigenin 5-O-beta-D-glucopyranose saponin, the content measuring is indicated as measuring the content of saponin in medicinal materials with the method of ultraviolet spectrophotometry. Compared to the existing technology, the invention brings forward a reineckea carnea thin-layer chromatography identification process and total saponin content measuring process with taking kitigenin and kitigenin 5-O-beta-D-glucopyranose saponin as reference substance, which perfects the quality detecting standard of reineckea carnea medicinal materials, recuperates the deficiency of the existing quality detecting technology, makes this quality detecting technology more scientific and reasonable, and ensures its security and validity in clinical application.

The invention discloses an amino sugar thiazole derivative as well as a synthetic method thereof. When synthesis is carried out, glucosamine hydrochloride is taken as a raw material, and benzyl ether protection is carried out on hydroxy, so that the selective reaction of amino is realized, a novel intermediate glycosyl thiourea-N-(1,3,4,6-tetra-0-benzyl-2-deoxygenation- beta-D-glucopyranose-2-group) thiocarbamide is synthesized, and glycosyl thiazole-N-(1,3,4,6-tetra-0-benzyl-beta-D-glucopyranose-2-group)-2-amido-4-substituted thiazole is synthesized by cyclizing the novel intermediate glycosyl thiourea-N-(1,3,4,6-tetra-0-benzyl-2-deoxygenation beta-D-glucopyranose-2-group) thiocarbamide with 1-bromine-2-substituted ethyl ketone. The synthetic method disclosed by the invention has the advantages of easiness and safety for operation, wide application scope, low cost of the raw material, easiness for raw material obtaining, easiness and convenience for post-processing and high yield, is a fast high-efficiency synthetic method and has a wide application prospect on the aspect of preparing an acetylcholinesterase resistant drug because the synthesized compound has high inhibiting effect on acetylcholinesterase.

The invention belongs to the field of preparation and utilization of secondary metabolism active components of forestry processing residues, and concretely relates to a technology for preparing a caffeoyl group-containing tannin derivative 1,3-di-O-galloyl-6-O-caffeoyl-beta-D-glucopyranose from Juglandaceae Juglans Juglans sigillata tree leaves, and an application of the derivative in the preparation of anti-oxidation products. The technology has the advantages of standardized extracting and separating preparation process, high yield, low cost and simple operation.

The invention provides a method for preparing the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose. At a room temperature, 2-Amido-2-deoxy-D-glucopyranose hydrochloride serves as a raw material, imidazole-1-sulfonyl azide hydrochloride serves as a nitrine reagent, a dowex1X8 resin serves as a acid-binding agent for acylation, silylation and sulfonylation, 1,8-Diazabicyclo-(5,4,0) undec-7-ene or the dowex1X8 resin serves as an alkali reagent for ring closing reaction, and the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose is synthesized through nitrine introduction, acylation reaction, silylation reaction, sulfonylation reaction and ring closing reaction in sequence; and the reaction process is represented as formula (I). The 1,-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose can serve as an intermediate for synthesizing anticoagulant drug fondaparinux sodium. The method for preparing the 1,6-Anhydro-2-azido-2-deoxy-beta-D-glucopyranose has the advantages of being mild in reaction, simple in synthetic route, low in cost, safe and reliable, and suitable for large scale production.

The invention provides a quality control method of a Chinese medicinal hindu datura flower capsule for treating psoriasis. The psoriasis is a skin disease with complicated and unclarified pathogenesis. The method comprises the following steps: performing thin layer chromatography to determine whether the effective position of the hindu datura flower capsule contains 3-O-beta-D-glucopyranose, hindu datura glucoside C, 5 alpha,12 beta,27-trihydroxy-6alpha,7alpha-epoxy, 20R,22R, -1-ketone-witha-2,24-diene lactone-27-O-beta-D-glucopyranoside and alkaloids or not; detecting the contents of total flavonoids and total steroids in the effective position of the hindu datura flower capsule by using an ultraviolet spectroscopy method; detecting the contents of the 3-O-beta-D-glucopyranose (1->2) glucopyranose-7-O-alpha-L-rhamnopyranose tiliroside and the hindu datura glucoside C by using a reversed phase highperformance liquid chromatography method; and establishing limit test of alkaloids in the effective position of the hindu datura flower capsule. The quality control method is used in quality control of the hindu datura flower capsule.

The invention relates to a method for preparing rare ginsenoside CK from protopanaxadiol ginsenoside through fermentation of microbacterium oxydans, in particular to a method for preparing 20-O-beta-D-glucopyranose-20-protopanaxadiol ginsenoside from protopanaxadiol ginsenoside Rb1, Rd and the like converted by utilizing fermentation of microbiological strains in a fully-automatic fermentation tank, belongs to the technical field of medicine, and comprises the steps: (1) fermentation cultivation of bacterial strains; conversion of raw materials Rb1, Rd and the like by utilizing fermented microorganisms and taking heteropolyacid HxYW12O40.nH2O with a Keggin structure as a catalyst, wherein Y is selected from P, Si, Fe or Zn, x is 3 or 4, and n is a positive integer ranging from 0 to 30; (3) preparative chromatographic separation and purification of conversion products, so as to finally obtain a compound with the chemical name being 20-O-beta-D-glucopyranose-20-protopanaxadiol ginsenoside.

The invention relates to a novel type 2 diabetes resistant drug canagliflozin impurity compound [2-methyl-5-(beta-D-glucopyranose)phenyl][5-(4-fluorophenyl)-2-thienyl]methyl hydroperoxide (a compoundof a formula IV) and a preparation method thereof, and application of the impurity compound serving as a canagliflozin quality control reference standard substance.

The invention provides an application method of 1, 3, 4-3-tri-O-galloyl acyl -6-O- caffeoyl-Beta-D- glucopyranose in preparing tumor antitumor drugs, in particular the application of glucoseglucopyranose in preparing inducing agent to inhibit the growth of tumor cells and to accelerate tumor cell apoptosis. The invention also provides a tumor antitumor drug, which contains 5 to 20 percent of 1, 3, 4-3-tri-O-galloyl acyl -6-O- caffeoyl-Beta-D- glucopyranose.

The invention relates to the medical technical field, in particular to a pentacyclic triterpene compound which is separated to be obtained from a ranunculaceae plant of pulsatilla cernua (Thunb.) Bercht.et Opiz, and the chemical structural formula is shown in the accompanying drawing, wherein glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose, and the compounds A and B are respectively a new compound. Cell experiments in vitro show that the compound has a remarkable protection function to neuroblastoma cell strain SH-SY5Y induced by A beta (25-35). The compound disclosed by the invention has the advantages of simpleness in preparation and remarkable activity. The invention provides the new compound for preventing and curing AD (Alzheimer's Disease). In the invention, the glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose.

The invention belongs to the field of tobacco spices, and particularly relates to the application of 6-0- acetyl-2,3,4-tri-0-isobutyryl-Beta-D-glucopyranose in cigarette. The invention is characterized in that 6-0- acetyl-2,3,4-tri-0-isobutyryl-Beta-D-glucopyranose is added into cigarette in the proportion of 0.05-10 Mug/g to tobacco. By adding 6-0- acetyl-2,3,4-tri-0-isobutyryl-Beta-D-glucopyranose in cigarette, the application can acquire the optimum effect.

The invention provides a novel hydrolytic tannins of the pyran glucose category containing the gall acyl, particularly a 1,3-O-2-galloyl-6-O-(S)-caesalpinia digyna acyl-beta-D-glucopyranosyl dextrose. The chemical structure is as shown in formula (1). The compound of the invention can inhibit the proliferation of tumor; the compound has the better anti-tumor activity and can be used to prepare the anti-tumor drug.

The invention relates to a glucosamine-containing 1,3,4-thiadiazole derivative and a synthesis method of the lucosamine-containing 1,3,4-thiadiazole derivative. The method comprises the following steps: reacting 2-desoxy-2-isorhodanate-1,3,4,6-tetra-O-benzyl-beta-D-glucopyranose with hydrazine hydrate to synthesize an intermediate glycosyl thiosemicarbazide, and reacting with substituted aldehyde and a Fe<3+> compound to synthesize the N-(5-substituted-1,3,4-thiadiazolyl-2-yl)-1,3,4,6-tetra-O-benzyl-2-desoxy-beta-D-glucosamine. The synthesis method is simple and safe to operate, and has the advantages of small environmental pollution, high yield and simple after-treatment. The synthesized compound has a strong inhibiting effect on acetylcholinesterase, and has wide application prospects in the aspect of preparation of anti-acetylcholinesterase drugs.

The invention relates to a benzo-dihydropyran glycoside derivatives whose structure is illustrated by formula (I) disclosed in the specification, the derivative is prepared through using corresponding hydroquinone or hydroxybenzene as starting raw material, then carrying out methylation, 1,2,3,4,substitution of phenyl ring by 6-penta-O-acetyl-beta-D-glucopyranose, benzene quinonization, hydrogen quinonization, cyclisation and alcoholysis. In formula (I), R1, R3 are selected from H, CH3 and one of (II), R2 is C1-C16 alkyl, R4 is H or CH3, wherein at least one of R1 and R3 is (III) but R1 and R3 cannot be (IV) at the same time.

The invention provides a Diwu extract with a mass content of 60%, which mainly comprises Diwu saponins, the four monomers are, 3-O-beta-D-pyran glucuronic acid-oleanolic acid-28-O-alpha-L-pyran rhamnose(1-4)-beta-D-glucopyranose(1-6)-beta-D-glycopyraniside, 3-O-beta-D-glucopyranose aldehyde acid-oleanolic acid-28-O-beta-D-glucopyranose(1-6)-beta-D-glucopyranoside, 3-O-alpha-L-pyran rhamnose(1-2)-beta-D-glucopyranose-oleanolic acid-28-O-alpha-L-pyran rhamnose(1-4)-beta-D-glucopyranose(1-6)-beta-D-glycopyraniside, 3-O-alpha-L-pyran rhamnose(1-2)-alpha-L-Arabinopyranosyl-oleanolic acid-28-O-alpha-L-pyran rhamnose(1-4)-beta-D-glucopyranose(1-6)-beta-D-glycopyraniside. The invention also discloses the process for preparing the abstract.